Get the Stockscreener App
3.59
4.36%
0.15
After Hours:
3.65
0.06
+1.67%
Neuphoria Therapeutics Inc stock is traded at $3.59, with a volume of 98,313.
It is up +4.36% in the last 24 hours and down -20.04% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$3.44
Open:
$3.32
24h Volume:
98,313
Relative Volume:
1.49
Market Cap:
$19.40M
Revenue:
$15.00M
Net Income/Loss:
$2.71M
P/E Ratio:
2.8212
EPS:
1.2725
Net Cash Flow:
$-2.89M
1W Performance:
-17.85%
1M Performance:
-20.04%
6M Performance:
-9.57%
1Y Performance:
-49.86%
1-Day Range:
$3.32
$3.7469
1-Week Range:
$3.19
$4.6433
52-Week Range:
$3.19
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.59 | 18.59M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
NEUPNeuphoria Therapeutics Inc Latest SEC Filings - Finviz
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership - MSN
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Asianet Newsable
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer's Drug Trial Under Neuphoria Partnership - Menafn
Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics - Moomoo
Neuphoria confirms merger talks with Scancell Holdings - Investing.com UK
Neuphoria confirms merger talks with Scancell Holdings By Investing.com - Investing.com Nigeria
Neuphoria Therapeutics (NEUP) Confirms Acquisition Talks with Sc - GuruFocus
Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85. - Bitget
Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell - TradingView
Neuphoria TherapeuticsConfirms Discussions - Moomoo
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewswire
Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP) - TradingView
Scancell in talks for reverse merger with Neuphoria Therapeutics - Investing.com
Scancell confirms advanced talks over reverse merger with Neuphoria - Proactive financial news
Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq - marketscreener.com
Scancell in talks for reverse merger with Neuphoria Therapeutics By Investing.com - Investing.com Canada
NEUP Forecast — Price Target — Prediction for 2027 - TradingView
Scancell confirms advanced reverse merger talks with US-listed Neuphoria - Share Talk
Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria - marketscreener.com
Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuphoria Therapeutics Inc (NEUP) Institutional Confidence - TradingKey
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuphoria Therapeutics Inc (NEUP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics (NEUP) Holds Near Support With Minimal Price MovementFundamental Weighted - Město Břeclav
NEUP Q1 2026 Earnings: Surprise EPS Beat Highlights Cost Discipline Despite Pre-Revenue StatusOne-Time Loss Impact - lwvtexas.org
Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings - TradingView
Neuphoria Therapeutics (NEUP) Registration filing Summary - Quartr
NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No RevenueBook Value Growth - The Legal Advocate
NEUP Q1 2026 Earnings: Significant EPS Beat Amidst Revenue AbsenceCapex Guidance - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower as Consolidation Continues Near SupportFlat Correction - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower Amid Consolidation Near SupportBollinger Band - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowed Loss Surprises as Pre-Revenue Stage ContinuesPreliminary Results - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowing Losses Beat Estimates Sharp, Yet Shares SlipRevenue Guidance Update - The Legal Advocate
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial - The Globe and Mail
Neuphoria Therapeutics (NEUP) Holds Steady Near Support – Can the Range Hold?Fibonacci Arc - newsline.com
Neuphoria Therapeutics (NEUP) Slips Amid Sector Headwinds – Key Support Levels in FocusSize Factor - The Legal Advocate
Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish BreakoutKey Reversal Day - Newser
NEUP Q1 2026 Earnings: Wider-Than-Expected Loss Narrows Sharply as Clinical Pipeline Progress Drives Investor OptimismEPS Surprise History - The Legal Advocate
NEUP Q1 2026 Earnings: Steeper-Than-Expected Loss Narrowing Fuels Post-Report RallyEarnings Surprise Score - Newser
What Neuphoria Therapeutics (NEUP)'s +1.62% Jump Means for Investors 2026-05-21Wave Extension - The Legal Advocate
NEUP Stock Moves Higher as Traders Focus on Neuphoria’s Cash Runway - Bez Kabli
Neuphoria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):